NASDAQ · Biotechnology · USD

ImageneBio, Inc. (IMA) Stock Analysis

ImageneBio, Inc. (IMA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMA

$4.09

−$0.04 (−1.09%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMA with… →

IMA Key Statistics

As of Oct 21, 2026

Trading

Open: $4.14
Previous Close: $4.13
Day's Range: 4.07–4.18
52-Week Range: 3.90–9.10
Volume: 7.09K

Valuation

Market Cap: $46.46M
P/E Ratio: unprofitable
EPS (ttm): −4.09

Financials (FY)

Revenue (FY): $800.00K−77.14%
Net Income (FY): −$45.35M
Shares Outstanding: 11.37M
1-Year Return: −45.39%

Dividend and dates

Avg Volume: 13.43K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMA closed at $4.09, −45.39% over 1 year.

ImageneBio, Inc. (IMA) has a market capitalization of $46.46M.

In fiscal 2025, IMA reported revenue of $800.00K.

IMA Stock Return by Calendar Year

ImageneBio, Inc. (IMA) return since Mar 2021: what $10,000 became

1 year: $10,000 $5,461; −45.39%
5 years: $10,000 $305; −96.95%
Since Mar 2021: $10,000 $106; −98.94%

If you had invested $10,000 in ImageneBio, Inc. (IMA) at the close on March 26, 2021, the earliest close on record here, it would have been worth $106 at the close on October 21, 2026: −98.94% in total, −55.76% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−60.81%−78.79%−25.94%−16.75%−64.94%−40.80%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−40.80%
2025	−64.94%
2024	−16.75%
2023	−25.94%
2022	−78.79%
2021 (partial year)	−60.81%

As of October 21, 2026.

IMA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$800.00K	−$45.35M	−5,668.6%
2024	$3.50M	−$36.57M	−1,044.8%
2023	$7.96M	−$21.15M	−265.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$800.00K	—	−$48.45M	−$45.35M	−5,668.6%
2024	$3.50M	—	−$37.00M	−$36.57M	−1,044.8%
2023	$7.96M	—	−$21.93M	−$21.15M	−265.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ImageneBio, Inc. (IMA) carries a market capitalisation of $46.46M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 18 employees.

IMA last closed at $4.09 on October 21, 2026. That is −$0.04 (−1.09%) against the previous close. Over the past 52 weeks the price has ranged from $3.90 to $9.10. The latest close sits 4.74% above that 52-week low.

Financial Health

In fiscal 2025, ImageneBio, Inc. reported revenue of $800.00K. That is −77.14% against the prior fiscal year, when revenue was $3.50M. The same year closed with a net loss of $45.35M. Trailing earnings per share are −4.09.

Across the 3 fiscal years on file, revenue moves from $7.96M in 2023 to $800.00K in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is −45.39%. Measured over 5 years, that is −50.24% a year compounded. Annualized volatility over the trailing 5 years is 87.37%.

Growth & Income

The record shows no dividend for IMA.

Across the complete calendar years on file, 2024 returned −16.75% and 2022 returned −78.79%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the total return is −40.80%.

Peer Comparison

ImageneBio, Inc. (IMA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ImageneBio, Inc.	IMA	$46.46M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. ImageneBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Visit website →